We would like to share our experience of a masked/variant BCR-ABL-positive CML patient showing a t(11;22)(q23;q11.2) who is successfully treated with tyrosine kinase inhibitors (TKIs). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.